We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Brooklyn ImmunoTherapeutics Inc | AMEX:BTX | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.79 | 0 | 01:00:00 |
Delaware
|
001-11460
|
31-1103425
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
140 58th Street, Building A, Suite 2100
|
||
Brooklyn, New York
|
11220
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
Common Stock
|
BTX
|
NYSE American
|
Item 9.01 |
Financial Statements and Exhibits.
|
(a) |
Financial Statements of Business Acquired
|
|
• |
audited financial statements of Brooklyn LLC as of, and for the fiscal years ended, December 31, 2020 and 2019; and
|
|
• |
audited financial statements of Brooklyn LLC as of December 31, 2019 and 2018 and for the fiscal year ended December 31, 2019, the period from November 6, 2018 through December 31,
2018, and the period from January 1, 2018 through November 5, 2018.
|
(b) |
Pro Forma Financial Information
|
(d)
|
Exhibits
|
Exhibit
No.
|
Description
|
|
Consent of Marcum LLP
|
||
Audited financial statements of Brooklyn ImmunoTherapeutics LLC as of, and for the fiscal years ended, December 31, 2020
and 2019.
|
||
99.2
|
Audited financial statements of Brooklyn ImmunoTherapeutics LLC as of December 31, 2019 and 2018 and for the fiscal year ended December 31, 2019, the period from
November 6, 2018 through December 31, 2018, and the period from January 1, 2018 through November 5, 2018
|
|
Unaudited pro forma condensed combined financial statements of Brooklyn ImmunoTherapeutics, Inc. for the year ended December 31, 2020, including notes thereto
|
BROOKLYN IMMUNOTHERAPEUTICS, INC.
|
||
Dated: April 29, 2021
|
By:
|
/s/ Howard J. Federoff
|
Howard J. Federoff
|
||
Chief Executive Officer and President
|
1 Year Brooklyn ImmunoTherapeut... Chart |
1 Month Brooklyn ImmunoTherapeut... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions